Significant Ownership of Citius Pharmaceuticals, Inc.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Citius Pharmaceuticals, Inc. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Leonard Mazur - Leonard Mazur, Chief Executive Officer
- Manager location
- Cranford, NJ
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Citius Pharmaceuticals, Inc. with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Citius Pharmaceuticals, Inc.
Significant Ownership of Citius Pharmaceuticals, Inc.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| CTOR | Citius Oncology, Inc. | Common Shares, $0.0001 par value per share | 71% | $59,444,654 | 66,049,615 | 0% | Citius Pharmaceuticals, Inc. | 15 May 2026 |
Schedules 13D/G Reported by Citius Pharmaceuticals, Inc.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.